ISPE-CaSA Technology Life Sciences Show

Overview

This event brings together pharmaceutical and biopharmaceutical professionals—from students and emerging leaders to senior executives in drug manufacturing, supply chain, devices, services, and regulatory agencies.

This event focuses on the future of pharmaceutical sciences and manufacturing. Attendees will experience compelling educational sessions, industry-relevant presentations, and opportunities to share progress, best practices, and lessons learned.

February 25, 2026 7:00am - February 25, 2026 6:00pm

Raleigh Convention Center
500 S Salisbury Street
Raleigh, NC 27601

$50

Biomanufacturing

June 24, 2026

Concept to Commercialization: An Owner’s Perspective on the Modern Pharma Project Lifecycle

This event brings together life sciences leaders to discuss the realities of navigating today’s pharmaceutical projects, from early planning and design through startup, validation, and commercial readiness.

Panelists will discuss owner-side perspectives on project execution, operational readiness, collaboration, and the evolving challenges shaping modern life sciences facilities and manufacturing environments.

Featured Panelists:

September 17, 2026

UNC Women's Health Research Symposium

The inaugural Women's Health Multidisciplinary Research Symposium, to be held at UNC, will foster interdisciplinary connections, collaboration, and knowledge sharing among trainees and faculty passionate about women’s health research.

This symposium is hosted by the Women’s Health Multidisciplinary Consortium (WHMC) and the Department of Pathology and Laboratory Medicine and supported by the Center for Women’s Health Research and the School of Medicine’s Department of Obstetrics & Gynecology.

June 18, 2026

United Therapeutics receives FDA clearance for xenoheart clinical trial

United Therapeutics Corporation, a public benefit corporation with co-headquarters in Research Triangle Park, has received U.S. Food and Drug Administration (FDA) clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart xenoheart derived from a pig.